Skip to content

Metacognitive therapy for those at high risk of developing psychosis

MetaCognitive Therapy for those meeting At Risk Mental State criteria: a pilot study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN53190465
Enrollment
10
Registered
2019-02-06
Start date
2014-03-06
Completion date
Unknown
Last updated
2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

At Risk Mental State (at risk of psychosis) Mental and Behavioural Disorders At Risk Mental State (at risk of psychosis)

Interventions

The MCT intervention consisted of 12 sessions over a period of 12 weeks following baseline assessment, and followed the treatment manual developed by Wells (Wells, 2011). For the purpose of this study
Morrison et al., 2014). The metacognitive model asserts that psychological distress results from extended processing in response to negative cognitions (comprising thoughts, images, voices etc). Examp

Sponsors

Greater Manchester Mental Health NHS Foundation Trust
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Have an identified case manager 2. In contact with mental health services 3. Meet entry criteria for an Early Detection and Intervention Team (for those at high risk of developing psychosis) operationally defined using the CAARMS 4. Judged by their clinician/case manager to be clinically stable for at least the previous 4 weeks

Exclusion criteria

Exclusion criteria: 1. Moderate to severe learning disability 2. Evidence of clear organic neurological impairment (e.g., head injury or dementia) 3. Non-English speaking in so far as this would prevent the use of standardised assessment instruments 4. Inpatient/acute care required immediately prior to or during baseline assessment 5. Taking prescribed antipsychotic medication 6. Absence of case management 7. Primary diagnosis of substance dependency

Design outcomes

Primary

MeasureTime frame
1. Recruitment, measured by number of referrals and number consenting at the baseline 2. Retention, measured by percentage follow-up and questionnaire response rates after 3 and 6 months

Secondary

MeasureTime frame
All measures were administered at the end of treatments (3 months post baseline) and at a 6 month follow-up: 1. At risk symptoms (psychotic-like experiences), assessed using the Comprehensive Assessment of At Risk Mental States (CAARMS) 2. Anxiety and depression, assessed using the Hospital Anxiety and Depression Scale (HADS) 3. Metacogntions, assessed using the Metacognitions Questionnaire 30 (MCQ30) 4. Hypothetical interpretations of voices, assessed using the Interpretation of Voices Inventory (IVI) 5. Beliefs about paranoia, assessed using the Beliefs About Paranoia Scale (BAPS) 6. Worry, assessed using the Anxious Thoughts Inventory 7. Cognitive attention, assessed using the The Cognitive Attention Syndrome Scale (CAS1)

Countries

United Kingdom

Contacts

Public ContactSophie Parker
sophie.parker@gmmh.nhs.uk+44 (0)161 358 1395

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 19, 2026